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Abstract: Alzheimer’s disease (AD) is a neurodegenerative disorder of the central nervous system manifested by cogni-
tive and memory deterioration, a variety of neuropsychiatric symptoms, behavioral disturbances, and progressive impair-
ment of daily life activities. Current pharmacotherapies are restricted to symptomatic interventions but do not prevent 
progressive neuronal degeneration. Therefore, new therapeutic strategies are needed to intervene with these progressive 
pathological processes. In the past several years adenosine, a ubiquitously released purine ribonucleoside, has become im-
portant for its neuromodulating capability and its emerging positive experimental effects in neurodegenerative diseases. 
Recent research suggests that adenosine receptors play important roles in the modulation of cognitive function. The pre-
sent paper attempts to review published reports and data from different studies showing the evidence of a relationship be-
tween adenosinergic function and AD-related cognitive deficits. Epidemiological studies have found an association be-
tween coffee (a nonselective adenosine receptor antagonist) consumption and improved cognitive function in AD patients 
and in the elderly. Long-term administration of caffeine in transgenic animal models showed a reduced amyloid burden in 
brain with better cognitive performance. Antagonists of adenosine A2A receptors mimic these beneficial effects of caffeine 
on cognitive function. Neuronal cell cultures with amyloid beta in the presence of an A2A receptor antagonist completely 
prevented amyloid beta-induced neurotoxicity. These findings suggest that the adenosinergic system constitutes a new 
therapeutic target for AD, and caffeine and A2A receptor antagonists may have promise to manage cognitive dysfunction 
in AD. 
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INTRODUCTION 
  Alzheimer’s disease (AD) is a progressive neurodegen-
erative  disease  associated  with  the  most  common  form  of 
dementia in the elderly and accounting for around 50-60% of 
dementia  in  any  age  group  [15].  The  cause  of  AD  is  un-
known,  only  a  small  number  of  cases  (<1%)  have  known 
genetic causes [33]. Genetic studies have found linkage be-
tween familial AD and presenilin 1(PS-1; chromosome 1), 
presinilin 2 (PS-2; chromosome 14) and amyloid precursor 
protein gene (APP; chromosome 21) [89]. The elderly age is 
the most significant non-genetic risk factor and AD is rare 
below the age of 50 [89]. 
  The deposition of extracellular amyloid plaques contain-
ing amyloid beta (Aβ)  peptide  and formation of intraneu-
ronal  neurofibrillary  tangles  are  classical  histopathological 
hallmarks of AD [68]. These findings are pronounced in the 
hippocampus, entorhinal cortex, amygdala, and cerebral cor-
tex [89]. Aggregation of soluble Aβ into oligomer and large 
fibrils in different region of brain parenchyma is considered 
to be a crucial event in AD onset [62]. Aβ protein consists of 
a  sequence  of  39-42  amino  acids  derived  from  the  trans-
membrane region of the APP [84]. The most predominant 
sequences of Aβ peptides are Aβ1-40 and Aβ1-42 [75]. Aβ1-42 
accumulates early in amyloid plaques and polymerizes into 
fibrils more rapidly than Aβ1-40 in vitro [13, 78]. Studies us-
ing transgenic mice expressing APP have provided signifi-
cant insight regarding the contribution of Aβ plaques to the  
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AD pathology. In APP transgenic mice plaques are associ-
ated with neuronal death, neuritic dystrophy, dendritic spine 
loss  and  abnormal  axonal  morphology  [90].  These  altered 
morphologies lead to disrupted synaptic transmission [132]. 
Neurofibrillary tangles are composed of microtubule associ-
ated  protein  tau,  normally  expressed  in  axons,  which  are 
abnormally hyperphosphorylated in AD and aggregate into 
abnormal filaments in the neuronal cell body [65]. The num-
ber of neurofibrillary tangles is related to the presence and 
degree of dementia in AD [8]. Mutations of PS-1, PS-2 and 
APP  in  AD  enhanced  the  processing  of  amyloidogenic 
Aβ from APP [124]. 
  In recent years,  adenosine, a purine ribonucleoside has 
drawn the interest of researchers for its neuromodulatory and 
neuroprotective effects in several neurological diseases. This 
endogenous  nucleoside  is  found  in  all  cells  including  glia 
and neurons, and plays important roles in the regulation of 
synaptic transmission and neuronal excitability in the central 
nervous system [38]. Adenosine exerts its cellular function 
through four G-protein coupled receptors (A1, A2A, A2B and 
A3) [56], regulates, integrates and fine-tunes neuronal activ-
ity and influences several important brain functions such as 
sleep and arousal, cognition and memory, neuronal damage 
and degeneration [48, 102, 113]. The predominant pharma-
cological effects of adenosine are mediated through A1 and 
A2A receptors. Several studies have investigated the expres-
sion of A1 and A2A receptors in AD [6, 74] and tested the 
effects of A1 and A2A receptor agonists/antagonists in animal 
models of AD [43, 104, 110]. Findings of enhanced cogni-
tive function [66] or protection against cognitive impairment 
by nonselective blockade of A1 and A2A receptors [7], and 
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acetylcholine by modulating these receptors, made these two 
receptors a prime target for the development of new thera-
pies for AD. In adult brain, adenosine concentration mainly 
depends on the activity of astrocyte-base enzyme adenosine 
kinase, which phosphorylates adenosine to AMP is consid-
ered to be the principal metabolic enzyme for the regulation 
of extracellular adenosine level in the brain [18]. Alternative 
metabolic routes for adenosine in brain  that involve  either 
deamination of adenosine to inosine by adenosine deaminase 
or reversible hydrolysis of S-adenosylhomocystein (SAH) by 
SAH hydrolase constitute minor pathways for the regulation 
of adenosine [18]. The role of adenosine kinase on adenosine 
metabolism in AD has not been studied yet.  
  Different  spatial  distribution  of  adenosine  receptors 
within the brain and their opposing effects after stimulation 
allow adenosine to exert a complicated effect for modulating 
other neurotransmitters [39]. The role of adenosine in differ-
ent neurological diseases including epilepsy, stroke, chronic 
pain, Parkinson’s, Huntington’s, and Alzheimer’s disease has 
been elaborated briefly in review [17] based on their success-
ful experimentation or clinical trial or therapeutic potential. 
This  review  attempts  to  summarize  the  role  of  adenosine 
reported in different studies and its diverse effects and asso-
ciation with AD. 
A1 RECEPTORS IN ALZHEIMER’S DISEASE 
  Adenosine  depresses  synaptic  transmission  and  the  re-
lease of various neurotransmitters acting through A1 recep-
tors  [58,  77].  In  the  hippopcampus,  adenosine  inhibits  the 
release of acetylcholine and the excitatory amino acid gluta-
mate  [27,  50,  58].  Glutamate  and  its  receptors  have  been 
implicated in the pathogenesis of AD and the dysfunction of 
this  excitatory  amino  acid  system  may  be  responsible  for 
some of the clinical manifestations of AD [32, 63]. Alexan-
dre de Mendoca first described that endogenous adenosine, 
through A1 receptor activation, modulates long-term synaptic 
plasticity phenomena, such as long-term potentiation (LTP) 
[45], and subsequently showed that the tonic activation of A1 
receptors decreases LTP, long-term depression and depoten-
tiation [46, 47]. In accordance with the notion that synaptic 
plasticity is the basis for learning and memory in different 
brain  areas  [16],  adenosine  correspondingly  modulates  ro-
dent  performances  in  various  learning  and  memory  para-
digms  [48].  Administration  of  adenosine  receptor  agonists 
(mainly A1) disrupts learning and memory in rodents [29, 67, 
97] while the nonselective adenosine receptor blockade by 
caffeine/theophylline  or  selective  blockade  of  A1  and  A2A 
receptors improve the performances of rodent different be-
havioral tasks [67, 88, 100].  
  A1 receptors are highly enriched in  the  CA1 region of 
hippocampus [53, 79] in a normal healthy brain. A change in 
the pattern of A1 receptor expression has been found in AD 
patients when compared with age-matched control brains [6]. 
Most of the studies carried out in AD models for adenosine 
receptors were performed in hippocampus and striatum and 
have  shown  reduced  levels  of  A1  receptors  in  these  areas 
[74]. In AD patients, a reduced density of A1 receptors along 
with  reduced  binding  sites  for  adenosine  agonists  and  an-
tagonists has been found in the molecular layer of the dentate 
gyrus. In addition, altered binding of adenosine agonists and 
antagonists to A1 receptors in CA1 and CA3 regions of hip-
pocampus has been observed [139]. Kalaria and colleagues 
have  demonstrated  that  A1  receptors  are  significantly  re-
duced  by  40-60%  in  AD  after  assessing  the  hippocampal 
samples collected from postmortem AD subjects. They also 
observed the highest reduction of A1 receptors in the molecu-
lar layer of the dentate gyrus including perforant pathways 
[82], which is the principal source of cortical input to  the 
hippocampal  formation  [73].  However,  little  was  known 
about A1 receptors in the frontal cortex of AD until a very 
recent  study  reported  by  Albasanz  et  al.  [2].  The  authors 
have shown that upregulation of A1 and A2A receptors take 
place in frontal cortex both in early and advanced stages of 
AD, associated with sensitization of the corresponding trans-
duction pathways. In agreement with theses results, a study 
carried-out in a transgenic mouse model (APP Swedish mu-
tation) also found the higher levels of cortical A1 and hippo-
campal A2A receptors as compared with the non-transgenic 
mouse [7]. The loss of A1 receptors appears to be among the 
factors responsible for cell death in CA1 [98, 117]. 
  It is not clear whether A1 receptors influence the proc-
esses  involved  in  the formation of  abnormal APP and  the 
formation of hyperphosphorylated tau in AD patients. How-
ever, the role of A1 receptors in APP processing, tau phos-
phorylation  and  cellular  signaling  has  been  studied  in  a 
model using human neural cells (neuroblastoma SH-SY5Y 
cells) that naturally express A1 receptors [6]. In this study, 
activation of A1 receptors  led to the production of soluble 
APP, which was confirmed by the use of the A1-selective 
antagonist  DPCPX.  A1 receptors  mediate  tau  phosphoryla-
tion and its translocation towards the cytoskeleton of neuro-
blastoma cells. A marked increase in A1 receptor immunore-
activity has been found in degenerating neurons with neu-
rofibrillary tangles and in dystrophic neurites of Aβ plaques 
in the hippocampus and frontal cortex of AD. A significant 
co-localization of A1 receptors and Aβ in senile plaques and 
of A1 receptors and tau in neurons with tau deposition has 
been found [6]. The positive involvement of A1 receptors in 
in vitro APP processing and in tau phosphorylation and the 
presence of A1 receptors in the neurodegenerative structures 
of  AD  suggest  that  A1  receptors  may  play  a  role  in  the 
pathogenesis of AD.  
A2A RECEPTORS IN ALZHEIMER’S DISEASE 
  A2A receptors have low expression in healthy brain but 
this pattern of expression and functionality can be changed in 
pathological conditions. Limited data is available about the 
distribution of A2A receptors in AD. An increased expression 
of A2A receptors in microglial cells in the hippocampus and 
cerebral  cortex  of  AD  patients  has  been  found  [6].  Long-
term noxious stimuli  to  the brain increase  the density and 
efficiency of A2A receptors, which has been observed in ani-
mal models of Parkinson’s disease [101]. Some other studies 
also depicted the up-regulation of A2A receptors in chronic 
stressful condition, which prevail in neurodegenerative dis-
eases, with simultaneous decrease in the density of cortical 
A1 receptors [108]. Apart from AD, adenosine A2A receptors 
have also been detected in the cerebral cortex of other neu-
rodegenerative diseases such as Pick’s disease and a marked 
increase  in  A2A  receptors  has  been  detected  in  the  frontal 
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  Modulation of A2A receptors could have neuroprotective 
effects in AD, in a way that it might interfere the pathogene-
sis of AD  and increase the resistance of neuronal cells to 
insults. The prevailing hypothesis for progressive neurode-
generation that occurs in AD is the neurotoxicity caused by 
Aβ [144] and current evidence favors the  idea that soluble 
Aβ plays the pivotal role in the pathogenesis of AD. Primary 
cultures  of  cerebellar  granule  cells  with  Aβ 25-35  in  the 
presence  of  adenosine  receptor  blockers  revealed  that  the 
blockade  of  A2A  receptors  almost  completely  prevented 
Aβ induced neurotoxicity [43]. So it appears  that the pres-
ence of A2A receptor is essential for Aβ toxicity and inactiva-
tion of this receptor might limit the Aβ induced neurotoxicity 
in AD. The mechanism of neuroprotection by A2A receptor 
antagonists against Aβ induced neurotoxicity is not known. 
One  plausible  hypothesis  might  be  its  ability  to  modulate 
neuro-inflammation by its anti-inflammatory properties [61]. 
  Symptomatic benefit from cognitive impairment in AD 
patients might be achieved by modulating A2A receptors as 
these  receptors  could  facilitate  the  neurophysiological 
mechanisms  of  learning  and  memory.  Several  studies  re-
vealed the potential modulatory role of brain A2A receptors 
on learning, memory and other cognitive functions [36, 121]. 
Delayed memory deficits induced by intracerebroventricular 
Aβ were prevented by either caffeine or selective A2A recep-
tor  antagonists  [42].  This  result  indicates  that  caffeine  af-
fords its beneficial effects through A2A receptors, which were 
found to be up-regulated in cortical regions both in animal 
models [7] as well as in cortical tissues of patients with AD 
[2, 6]. The data collected from a recent report demonstrated 
that pharmacological blockade or genetic inactivation of A2A 
receptors has been found to attenuate memory loss induced 
by Aβ [36]. In A2A receptor knockout mice, administration of 
Aβ did  not  cause  learning  deficits  or  synaptotoxicity  [34], 
and  this  highlights  the  importance  of  the  A2A  receptor  in 
cognitive function. Aβ−induced cognitive disruption may be 
a result from synaptic dysfunction [25], so effective modula-
tion of synaptic location might be helpful to counteract this 
cognitive  impairment.  The  A2A  receptor  antagonist  ZM 
241385 enhanced social memory in healthy rats [103] and 
reversed social memory impairment in spontaneously hyper-
tensive rats [105] and this type of social memory is depend-
ent upon the integrity of hippocampus [11]. The A2A receptor 
antagonist SCH 58261, improved the performance of mice in 
an inhibitory avoidance task in a time and dose dependent 
manner  [88].  A2A  receptor  antagonists  usually  confer  the 
beneficial  effects  that have been found in different behav-
ioral studies in vivo. 
  In contrast with cognitive benefits found by antagonizing 
the A2A receptors, beneficial effects have also been reported 
by stimulating the A2A receptors in in vitro studies. Activa-
tion of A2A receptors by exogenous selective agonists facili-
tates the acetylcholine secretion and enhances glutamatergic 
synaptic transmission in hippocampus, but it is interesting to 
note that activation of these receptors by endogenous adeno-
sine has no influence in basal hippocampal synaptic trans-
mission  [37,  80,  127].  Enhancing  effects  of  A2A  receptor 
agonists  on  synaptic  transmission  has  been  found  more 
prominent  in  aged  animals  [110]  and  this  effect  is  most 
likely due to the increased expression of A2A receptor in the 
limbic cortex of aged rats [93]. Brain-derived neurotrophic 
factor (BDNF, a member of the neurotrophin family) and its 
specific  tyrosine  kinase  receptor  (TrKB)  are  highly  ex-
pressed in the hippocampus [87] and BDNF has an important 
role  over  synaptic  plasticity  in  adult  hippocampus  [95]. 
BDNF enhances LTP both in vivo [96] and in vitro [83] and 
this facilitatory action of BDNF upon LTP is completely lost 
upon blockade of A2A receptors and depletion of extracellu-
lar adenosine [55]. Neurotrophins are potent survival factors 
for developing and degenerative neurons [147]. A decrease 
in levels and/or reduced activity of neurotrophins has been 
implicated  in  the  pathophysiological  mechanism  of  many 
neurological  diseases  including  AD  [122].  So  the  use  of 
these naturally occurring neurotrophic factors poses promis-
ing therapeutic potential for the treatment of these neurologi-
cal disorders [122]. The neurotrophins cannot cross the blood 
brain barrier so an invasive approach is required for in vivo 
administration. Neurotrophins can use transmembrane tyro-
sine kinases, so an alternate pathway is to use transactivation 
pathway such as A2A receptor agonists, which can activate 
TrKB independent of neurotrophin binding [91, 147]. This 
A2A receptor induced facilitation of neurotrophins raises the 
interest to use A2A receptor agonists as a tool that can readily 
cross the blood brain barrier to potentiate neurotrophic ac-
tions in  the brain. Despite all  these beneficial effects, A2A 
receptor  induced  excitotoxic  glutamate  mediated  neuronal 
damage limits the option of A2A receptor agonists as a thera-
peutic  tool.  Moreover,  A2A  receptors  become  desensitized 
even  after  short-term  exposure  to  agonists  [126]  and  A2A 
receptor  agonist  mediated  desensitization  of  A1  receptors 
[99] made the A2A receptor agonism less favorable for thera-
peutic potential. Although these in vitro stimulatory effects 
of A2A receptors are interesting, but generalizability of these 
effects to in vivo situation has its limitations and further re-
search is warranted in this regard.  
CAFFEINE AND ALZHEIMER’S DISEASE 
  Caffeine, the most widely consumed behavioral stimulant 
present primarily in coffee and tea acts most likely by in-
creasing  cortical  activity,  cerebral  energy  metabolism  and 
extracellular  acetylcholine  concentration  [93].  Increased 
state of alertness and arousal is experienced due to caffeine-
induced  CNS  stimulation [57]. Acetylcholine might be in-
volved in caffeine’s stimulant properties as cholinergic nerve 
terminals arising from forebrain cholinergic complex [125] 
have been involved in arousal and attentional processes [54, 
119]. Caffeine is one of the major contributors to the dietary 
antioxidants,  which  prevent  neurons,  and  other  cells  from 
free radical induced oxidative damage and thus reduce the 
risk of chronic degenerative diseases [134]. It also augments 
the rate of cerebral glucose utilization [57], which could con-
tribute to enhance cognitive function. Caffeine is a natural 
methylxanthine, a non-selective A1 and A2A adenosine recep-
tor antagonist, and a known neuromodulator with the asso-
ciative effect on cognitive function, motor behavior and in-
formation processing [57]. Activation of A1 receptors inhib-
its excitatory synaptic transmission through presynaptic in-
hibition of glutamate release [137] and at the postsynaptic 
terminal  it  inhibits  potassium  conductance  leading  to  neu-
ronal hyperpolarization [64]. The excitatory effects of caf-
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tagonism  might  explain  the  increased  cognitive  perform-
ances  found  with  habitual  caffeine  consumption.  The  A2A 
receptors  are  not  so  abundant  or  widely  distributed  in  the 
brain like A1 receptors and caffeine block these excitatory 
A2A receptors that has been reported neuroprotective consis-
tently in several studies [14, 42, 43]. The A2B and A3 recep-
tors are not well characterized and the role of caffeine over 
these two receptors is not well documented. The A2B recep-
tors are found to be involved in the modulation of normal 
synaptic transmission and long-term potentiation in the CA1 
region of the hippocampus [86], so this receptor might be of 
interest regarding AD related dementia.  
  The effect of caffeine on cognition is an unresolved ques-
tion and it is still debatable whether caffeine directly affects 
cognition [76]. There is a wealth of studies suggesting that 
the effects of caffeine on memory performance depend on 
the age [66, 76, 81, 114] and on the time of the day [10, 118] 
and sex [81, 114], but all these variables are often not ade-
quately controlled or incorporated in most of the studies. The 
role of caffeine and selective antagonist of A1 and A2A recep-
tors on cognitive function has recently been extensively re-
viewed by Takahashi and colleagues [135]. In this review, it 
has also been stated that the effects of caffeine and of A1 and 
A2A receptor antagonists primarily depends on the dose, the 
schedule and timing of administration, and on the mode of 
administration. Improved  memory performances in rodents 
have been observed after moderate doses of caffeine inges-
tion [5, 31, 104], whereas higher doses of caffeine disrupt 
memory acquisition [4, 28]. The effects of caffeine on mem-
ory retrieval showed mixed results with some studies show-
ing improvement [5, 4], while others have indicated either no 
response at all [59, 106] or even impairment in retrieval [28]. 
This  disruption  of  acquisition  or  retrieval  induced  by  caf-
feine might be due to the concomitant participation of both 
A1 and A2A receptors with various effects of different brain 
regions that control the different phases of memory process-
ing. The role of A1 and A2A receptors in the control of synap-
tic plasticity is particularly important for caffeine in restora-
tion of cognitive function when it is impaired. Inactivation of 
both A1 and A2A receptors has been found to counteract the 
age related cognitive decline [104]. Because of these cogni-
tion enhancement properties from combined blockade of A1 
and A2A receptors, caffeine has been proposed as a potential 
therapeutic  agent  to  reverse  age-related  cognitive  decline 
[115]. 
  A limited number of studies have investigated the rela-
tionship between coffee consumption and AD with regard to 
dementia or cognitive impairment. 
Experimental Animal Models 
  The  potential  neuroprotective  benefits  of  caffeine  con-
sumption are reported from long-term caffeine intake rather 
than  short-term  ingestion  that  have  been  typically  seen  in 
experimental models. Administration of caffeine shortly be-
fore  enhancing  cerebral  ischemia  showed  negative  effects 
[133] while chronic administration of caffeine to gerbils for 
4 weeks was able to reduce the neuronal damage in a model 
of  global  forebrain  ischemia.  The  animal  model  does  not 
spontaneously  develop  age-related  changes  that  resemble 
AD pathology. To model AD in rodents, the first transgenic 
mice model that represents several histopathological features 
of AD was the PDAPP mice [60] and more recently, trans-
genic mice that overexpress APP with high level of brain Aβ  
with aging have been developed [140]. Long-term caffeine 
administration  in  experimental  AD  (APPSW)  transgenic 
mouse has demonstrated significant improvement in multiple 
cognitive  tasks  compared  to  that  of  control  mice  [7].  Re-
duced  levels  of  soluble  Aβ fragments have  been  found  in 
these same  transgenic mice and  these effects are probably 
mediated  through  reduced  expression  in  PS-1  and  the 
β−secretase gene [7]. Caffeine also reduced the production 
of Aβ1−40 and Aβ1−42  peptides in neuronal cell cultures from 
these same transgenic mice [7]. Caffeine prevented neuronal 
damage and cognitive deficit caused by Aβ, an effect mim-
icked by A2A receptor antagonists [42, 43]. These results fur-
ther strengthen  the  idea  that  caffeine affords  its beneficial 
effects on  memory performance  through its action on A2A 
receptors. 
  An elegant study carried out by Herzog et al. has postu-
lated that there is a link between a hypofunctioning choliner-
gic system and age-related cognitive deficits and has shown 
that the medial prefrontal cortex of aged rats is less liable to 
release  acetylcholine  upon  depolarization  [71].  An  inverse 
relationship between adenosinergic and cholinergic systems 
has  been  reported  in  different  studies  where  acetylcholine 
release tends to reduce in aged brains while adenosine con-
tent is increased [35, 131]. Since adenosine can attenuate the 
release of several neurotransmitters including acetylcholine 
[30,  41],  it  might  be  plausible  to  postulate  that  adenosine 
accumulation plays an important role in age-related cognitive 
deficits and hence may be considered an interesting target for 
pharmacological manipulation. Caffeine has an influence on 
acetylcholine and its receptors in the brain whether it is ad-
ministered for a short time or a prolonged period. Admini-
stration of caffeine (both short-and long-term) to rats showed 
increased acetylcholine concentration in the prefrontal cortex 
without development of any tolerance that has been found in 
dopamine response [1]. The stimulatory effects of caffeine 
on acetylcholine release are probably mediated through A1 
receptors because blockade of A2A receptors by KF 17837 
does  not  affect  the  acetylcholine  release  from  rat  cortical 
slices [19]. Moreover, the A1 receptor antagonist DPCPX has 
been found to stimulate cortical acetylcholine transmission 
[1], which is in agreement with in vitro [19] and in vivo [21] 
studies showing that A1 receptors are involved at  multiple 
sites  of  action  in  regulating  cholinergic  neuronal  activity. 
Long-term  ingestion  of  caffeine  by  mice  exhibited  the  in-
creased number of muscarinic and nicotinic receptors in the 
brain and may also have increased cholinergic activity [128]. 
This  augmented  cholinergic  function  induced  by  caffeine 
would  greatly  benefit  AD,  where  the  cholinergic  function 
disrupts with progression of the disease. 
  Finally, a possible mechanism underlying the association 
of  caffeine  consumption  and  cognitive  functioning  can  be 
drawn from animal experiments. After consumption, caffeine 
enters the blood stream and acts as an A2A receptor antago-
nist in the brain [57] which stimulates the cholinergic neuro-
transmitters which in turn prevents Aβ−induced neurotoxic-
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Human Studies 
  A limited number of epidemiological studies have been 
conducted to determine the role of caffeine in neuroprotec-
tion and cognitive function in elderly and AD patients. The 
majority  of  epidemiological  studies  are  retrospective  case-
control studies that compare the risk factors for AD present 
in  AD  cases  with  nondemented  controls  [141].  Although 
there is no consensus from the result, several studies have 
indicated improved cognition after long-term caffeine con-
sumption. The effects of caffeine on cognition have consis-
tently been highest among the oldest age group. 
  Several studies of short-term caffeine consumption have 
largely found that caffeine induces small but significant im-
provements  in  vigilance  and  psychomotor  performances 
rather than improvements of higher-function such as memory 
and information processing [57, 111]. Scopolamine, a cho-
linergic  blocker  is  used  to  induce  cognitive  deficits  in 
healthy volunteers that mimic the cognitive deficits seen in 
AD. Short-term exposure of caffeine has been shown to im-
prove memory and cognitive function in the presence of sco-
polamine  induced  impairments  [116].  This  result  suggests 
that caffeine has specific memory enhancing properties and 
that the cholinergic pathway is involved in this process. 
  In contrast to the findings presented in short-term studies, 
multiple  studies  have  shown  that  long-term  (years  to  dec-
ades) caffeine consumption may result in improved cognitive 
function or may reduce the decline of cognition and memory 
that are found in AD and the aging process. Most of the lon-
gitudinal studies have consistently found the cognitive bene-
fits of long-term caffeine consumption among the group of 
oldest individuals.  
  A  case-control  study  performed  in  a  relatively  small 
number of subjects compared the daily intake of caffeine in 
AD patients with non-demented matched controls. The pa-
tients with AD had an average daily caffeine intake of 73.9 ± 
97.9 mg during the 20 years that preceded diagnosis of AD 
whereas the controls had an average intake of 198.7 ± 135.7 
mg during the corresponding 20 years. The main finding of 
this study was a significant inverse association between caf-
feine intake and AD, and this association was independent of 
other causative factors that might influence caffeine intake 
and potential risk factors for AD [94].  
  In a prospective study known as the “Three City Study” 
examined the association between caffeine intakes, cognitive 
decline and dementia incident among the subjects aged 65 
years  and  more.  This  4-year  long  population  based  study 
concluded without finding any relation between coffee con-
sumption and dementia in men but psychostimulant proper-
ties of caffeine appear to reduce cognitive decline in women 
without dementia especially at higher ages [114]. 
  A 10-year prospective cohort study (the FINE study) in 
676 men in Finland, Italy and the Netherlands found that the 
coffee  consumption  reduces  cognitive  decline  in  elderly 
men. Their findings suggest an inverse and J-shaped associa-
tion between the numbers of cups of coffee consumed and 
cognitive decline, with the least cognitive decline for men 
consuming three cups of coffee per day [143].  
  The Canadian Study of Health and Aging (CSHA), is a 
longitudinal study of dementia in elderly people that mainly 
focused on its prevalence, incidence  and risk factors.  Caf-
feine  was  one  of  the  factors  among  other  risk  factors;  al-
though this study was not specifically designed to assess the 
link of caffeine intake to AD. In this study, the daily coffee 
drinking has reduced the risk of AD by 31% among the age 
group of ≥65 years old during a 5-year follow-up [92]. The 
Manitoba Study of Health and Aging is a parallel study to 
the CSHA study, which found no influence of daily caffeine 
consumption  during  5  years  in  AD  incidence  after  adjust-
ment for age, sex, and education [138].  
  The most recent population-based study after an average 
follow-up of 21 years found that coffee drinkers at midlife 
had lower risk of dementia and AD at later life, compared 
with that of non-drinkers or little drinkers. The risk of de-
mentia reduced about 65% in people who drank 3-5 cups of 
coffee per day [52]. 
  Cross-sectional  studies  reported  contradictory  findings 
with some found cognitive benefit [66, 76] while others de-
picted inverse relation between coffee consumption and AD 
[20]. Habitual caffeine consumption may improve cognitive 
function in the elderly and it is widely believed that it might 
have a protective effect in AD [76, 81]. There are some stud-
ies  denoting  an  insignificant  or  no  role  at  all  for  caffeine 
consumption on cognition and AD [138, 142].  
  This  series  of  findings  presented  above  indicates  that 
caffeine and adenosine receptor antagonists affect memory 
performance both in humans and in animal models.  
TREATMENT OPTIONS 
  The  patients  with  AD  are  treated  clinically  principally 
with  anticholinestarase  inhibitor  and  N-methyl  D-aspartate 
receptor  antagonists,  have  been  shown  to  slow-down  the 
cognitive decline slightly. Antioxidant vitamin C and vita-
min E [51] also showed slight benefit and all these available 
treatments  are  only  confined  in  symptomatic  interventions 
and  they  do  not  prevent  neuronal  degeneration  and  death. 
Several important therapeutic strategies either in clinical trial 
or in preclinical stage are briefly summarized below. 1) Im-
munization against Aβ either active or passive is currently a 
widely adopted experimental approach which already been 
translated  into  human  clinical  trial  [123].  The  aim  behind 
this approach is to reduce the amyloid burden and enhance 
the clearing by redistributing the cerebral peptide to the sys-
temic circulation [44]. Active  immunization of APP trans-
genic mice provided highly desirable protection without any 
adverse  effect  influenced  for  safe  clinical  trail  in  mild  to 
moderate AD patient, which unfortunately halted because a 
small fraction of these patients experienced aseptic menin-
goencephalitis.  Further  improvement  for  this  vaccination 
therapy is underway to avoid the autoimmunity and proin-
flammatory reactions. 2) Inhibition of either of the two pro-
teases  β and γ−secretase,  that  produce  Aβ from  APP  is  an-
other target researchers are trying to explore. Immunization 
of mouse model with  Memapsin 2,  a β−secretase, reduces 
the level of Aβ [22]. 3) It has been observed that some non-
steroidal  anti-inflammatory  drugs  (NSAIDs)  exerts  benefi-
cial  effects by reducing neurotoxicity  in the brain and de-212    Current Neuropharmacology, 2009, Vol. 7, No. 3  Anisur Rahman 
crease  the  level  of  selective  Aβ42  without  inhibiting  the 
typical cyclooxygenase pathway [145], probably acting via 
allosteric modulation of γ−secretase. In a recent clinical trail 
NSAIDs  administered  to  patients  with  mild  cognitive  im-
pairment did not show any difference in the progression of 
AD  between  NSAIDs  and  placebo  [120,  136].  4)  Metal 
chelation has been proposed as a therapy of AD after finding 
association  of  metals  with  β−pleated  sheets  of  Aβ42 [67]. 
APP  transgenic  mice  treated  with  antibiotic  Clioquinol,  a 
well-known Cu
2+/Zn
2+ chelator has been found impeding the 
deposition of Aβ and this strategy is at the verge of clinical 
trial stage [24, 72]. 5) Increased level of cholesterol is asso-
ciated with a higher risk of cognitive impairment and demen-
tia and connection between serum cholesterol level and risk 
of AD is suggested  in several reports [107]. In preclinical 
studies high cholesterol-fed rabbit model exhibited increased 
accumulation of Aβ in brain and cholesterol-lowering drugs 
have  been  shown  to  reduce  pathology  in  transgenic  mice 
[112,  130].  Cholesterol  lowering  drugs  statins  are  already 
well prescribed, widely used and tolerated drugs, so any trial 
based on this drug will be well suited for human and which 
are in way for clinical trial. The current pharmacotherapy of 
AD mainly focused on two aspects, 1) to increase the avail-
ability of acetylcholine in the central cholinergic system and 
2)  to  ameliorate  behavioral  disturbances.  The  cholinergic 
hypothesis is supported by many studies, demonstrating that 
dysfunctional cholinergic system is sufficient to create mem-
ory deficit in animal models that are analogous to AD de-
mentia [12]. Moreover, degeneration of the cholinergic neu-
rons of the basal forebrain has been found in the brain of AD 
patients [9].  
  Due  to  profound  neuroprotective  and  neuromodulatory 
effects of adenosine [40],  adenosine receptors  in the brain 
have  drawn  high  research  interest  and  are  suggested  as  a 
potential target for therapeutic interventions in neurodegen-
erative diseases. Caffeine and A2A receptor antagonists may 
contribute  to AD pharmacotherapy by 1) augmenting cho-
linergic pathway and thus improving the cognitive functions 
and 2) by reducing brain Aβ burden and thus reducing the 
Aβ-induced  neurotoxicity.  It  is  well  documented  that  the 
cognitive protection by caffeine involves the blockade of A1 
receptors in hippocampus and cerebral cortex. Blockade of 
A1 receptors on cholinergic terminals has been shown to in-
crease  extracellular  levels  of  acetylcholine  [1],  a  neuro-
transmitter  particularly  important  for  cognitive  processing 
that dramatically decreased in AD brain. In AD, the A2A re-
ceptor is of high interest regarding therapeutic potential. A2A 
receptor  might  provide  symptomatic  benefit  and  cognitive 
enhancement  to  AD  patients.  Disturbances  in  declarative 
memory are usually the earliest and most prominent clinical 
symptoms associated with AD and the most affected brain 
regions are hippocampus and related anatomical structures, 
as well as basal forebrain nucleus that provide cholinergic 
innervation  to  the  hippocampus  and  neocortex  [109].  In-
creased density of A2A receptor in hippocampus of AD pa-
tients [6] and their location to presynaptic nerve terminals in 
hippocampus  made  them  a  suitable  target  for  controlling 
neurotransmitter  release  and  synaptic  function  [109].  Im-
proved  performance  found  in  different  behavioral  tasks  in 
animal studies is usually mediated by blocking A2A recep-
tors.  Consistent  cognitive  improvement  found  in  different 
longitudinal  studies  after  long-term  caffeine  consumption 
indicate that caffeine plays important role to prevent cogni-
tive decline in AD. A recent significant finding from an in 
vitro  study  gives  a  promising  breakthrough  that  caffeine 
could attenuate Aβ burden [7] and presence of A2A receptor 
is necessary for Aβ-induced neurotoxicity [43]. Therapeutics 
that reduces brain Aβ levels could provide cognitive benefit 
to AD that has been justified by improved cognitive function 
found in AD transgenic mice [26]. Enhanced cognitive func-
tion observed from nonselective blockade of A2A receptor by 
caffeine or by selective blockade of A2A receptors, made this 
receptor antagonist mechanism more favorable while explor-
ing AD treatment. Caffeine is quite potent, non-toxic and as 
effective as selective A2A receptor antagonists and the selec-
tive A2A antagonist has not proven superior to caffeine neu-
roprotection [23, 43]. It would be premature to recommend 
that therapeutic use of caffeine would halt or reduce the cog-
nitive decline in AD before performing rigorous pre-clinical 
and clinical trials on its therapeutic potential. But based upon 
the existing data collected from epidemiological studies of 
human caffeine consumption and from animal experimenta-
tion  that  pharmacological  agents  that  mimic  caffeine  and 
selective A2A receptor antagonists provides the rationale to 
evaluate their therapeutic potentials in the treatment of AD. 
CONCLUSION 
  In more than two decades since the adenosine receptors 
were cloned, quite a large number of studies reported from 
many  groups  throughout  the  world  highlight  the  role  of 
adenosine  in  different  systems  of  the  body.  The  role  of 
adenosine in brain function has received most attention due 
to  its  different  protective  and  modulating  effects  to  CNS. 
The  role  of  endogenous  adenosine  in  preventing  epileptic 
seizure is now a well-established fact drawn from different 
successful  studies  [146].  Selective  adenosine  A2A  receptor 
antagonists  are  currently  under  clinical  trials  for  treating 
Parkinson’s disease with encouraging results [85]. Different 
therapeutic approaches have been contemplated for treating 
AD,  the  most  common  and  devastating  neurodegenerative 
disease  of  human  intellect.  Cognitive  functions  are  badly 
affected and gradual deterioration is the inevitable outcome 
of this disease. Long-term effect of caffeine in AD patients 
seems to be most compelling among other proposed thera-
pies for AD. The paradoxical neuroprotective  effects from 
both activation and inactivation of A2A receptors reflect the 
complexity of actions of A2A receptors in CNS. Clear under-
standing of the cellular basis for neuroprotection afforded by 
A2A receptor antagonist would help to improve the design of 
clinical trials for AD. Time- and site-specific modulation of 
A2A receptors along with disease progression would benefit 
while formulating the adenosine-based therapy. Interpreting 
the data from epidemiological studies and animal models, it 
indicates that our understanding of the role of adenosinergic 
system in dementia is still far from complete. Complex inter-
action and plasticity between A1 and A2A receptors and their 
differential expression in different regions of the brain make 
it difficult to find the individual role and explicity of these 
two receptors. To achieve better understanding, integration 
between  different  types  and  phases  of  memory  as  well  as 
differential  expression  of  receptors  in  different  brain  area 
need to be evaluated. Combined neuroprotective findings of The Role of Adenosine in Alzheimer’s Disease  Current Neuropharmacology, 2009, Vol. 7, No. 3    213 
caffeine  on  cognitive  function  and  AD  incidence  in  both 
experimental  and  human  studies  are  quite  promising.  To 
answer some conflicting reports, it is important to standard-
ize the methodology of caffeine consumption measurement 
and relate the cognitive capacity with standard AD criteria. 
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